79 related articles for article (PubMed ID: 9264581)
1. Expression of the farnesyltransferase beta-subunit gene in human ovarian carcinoma: correlation to K-ras mutation.
Tanimoto H; Mehta KD; Parmley TH; Shigemasa K; Parham GP; Clarke J; O'Brien TJ
Gynecol Oncol; 1997 Aug; 66(2):308-12. PubMed ID: 9264581
[TBL] [Abstract][Full Text] [Related]
2. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas.
Khan SG; Dummer R; Siddiqui J; Bickers DR; Agarwal R; Mukhtar H
Biochem Biophys Res Commun; 1996 Mar; 220(3):795-801. PubMed ID: 8607844
[TBL] [Abstract][Full Text] [Related]
4. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
5. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.
Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
7. Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutation.
Caruso MG; Notarnicola M; Bifulco M; Laezza C; Guerra V; Altomare DF; Memeo V; Lorusso D; Demma I; Di Leo A
Scand J Gastroenterol; 2003 Jan; 38(1):80-5. PubMed ID: 12608469
[TBL] [Abstract][Full Text] [Related]
8. c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor.
Russo P; Arzani D; Trombino S; Falugi C
J Pharmacol Exp Ther; 2003 Jan; 304(1):37-47. PubMed ID: 12490573
[TBL] [Abstract][Full Text] [Related]
9. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
Sun J; Qian Y; Hamilton AD; Sebti SM
Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
[TBL] [Abstract][Full Text] [Related]
10. ras oncogene activation in human ovarian carcinoma.
van 't Veer LJ; Hermens R; van den Berg-Bakker LA; Cheng NC; Fleuren GJ; Bos JL; Cleton FJ; Schrier PI
Oncogene; 1988 Feb; 2(2):157-65. PubMed ID: 3285294
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase as a target for anticancer drug design.
Qian Y; Sebti SM; Hamilton AD
Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
[TBL] [Abstract][Full Text] [Related]
12. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
[TBL] [Abstract][Full Text] [Related]
13. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
14. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients.
Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J
Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
Brunner TB; Cengel KA; Hahn SM; Wu J; Fraker DL; McKenna WG; Bernhard EJ
Cancer Res; 2005 Sep; 65(18):8433-41. PubMed ID: 16166322
[TBL] [Abstract][Full Text] [Related]
16. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
[TBL] [Abstract][Full Text] [Related]
17. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
18. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.
Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M
Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950
[TBL] [Abstract][Full Text] [Related]
19. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
